Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13369471 | 1.00 | THRB (0.35) | THRBALDH1A1CNR1CNR2TSHR | |
| SCHEMBL4666901 | 0.85 | — | — | |
| SCHEMBL6744916 | 0.84 | ALDH1A1 (0.32) | ALDH1A1CNR1CNR2TSHRMAPK1 | |
| SCHEMBL28743191 | 0.82 | CNR2 (0.43) | ALDH1A1CNR1CNR2 | |
| SCHEMBL5702007 | 0.80 | ALDH1A1 (0.31) | ALDH1A1CNR1CNR2 | |
| SCHEMBL9419512 | 0.80 | ALDH1A1 (0.31) | ALDH1A1CNR1CNR2 | |
| SCHEMBL10444993 | 0.80 | LMNA (0.48) | THRBALDH1A1CNR1CNR2TSHR | |
| SCHEMBL10670026 | 0.80 | LMNA (0.48) | THRBALDH1A1CNR1CNR2TSHR | |
| SCHEMBL10782662 | 0.80 | MEN1 (0.44) | THRBALDH1A1TSHRMAPK1MEN1 | |
| SCHEMBL28269409 | 0.80 | LMNA (0.48) | THRBALDH1A1CNR1CNR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150306003-A1 | Injectable Amino-acid Composition | TOZZI DONNA M (US) | 2015-10-29 | — | — | US | disclosed |
| US-20120022241-A1 | Sophorolipid Analog Compositions | SyntheZyme, LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2181999-A1 | Method of manufacturing ruboxistarin | Zentiva, A.S. (CZ) | 2010-05-05 | — | — | EP | disclosed |
| EP-1061062-B1 | PROCESS FOR PRODUCING BUTANETRIOL DERIVATIVES | DAISO CO LTD (JP) | 2009-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022241-A1 | Sophorolipid Analog Compositions | LSS, CUTA, SMS | THRB 4735/4885ALDH1A1 3898/4885CNR1 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.